A multi-center and non-interventional registry of brentuximab vedotin in patients with relapsed or refractory CD30-positive lymphoma: the CISL1803/BRAVO study
CONCLUSION: The treatment outcomes of patients with relapsed or refractory CD30-positive lymphoma improved with BV treatment, and the safety profile was manageable.PMID:38031473 | DOI:10.5045/br.2023.2023206 (Source: Blood Research)
Source: Blood Research - November 30, 2023 Category: Hematology Authors: Seok Jin Kim Young Rok Do Ho-Sup Lee Won-Sik Lee Jee Hyun Kong Jae-Yong Kwak Hyeon-Seok Eom Joon Ho Moon Jun Ho Yi Jeong-Ok Lee Jae-Cheol Jo Deok-Hwan Yang Source Type: research
Cancers, Vol. 15, Pages 5669: A Retrospective Chart Review of Treatment Patterns and Overall Survival among a Cohort of Patients with Relapsed/ Refractory Mycosis Fungoides in France, Germany, Italy, Spain and the United Kingdom
Conclusions: High rates of R/R disease were observed after second- and third-line treatments in this real-world cohort, with longer median OS in patients receiving non-chemotherapy treatment versus chemotherapy. Following the standard management of MF and using recently approved targeted therapies can help improve patient outcomes in advanced-stage MF. (Source: Cancers)
Source: Cancers - November 30, 2023 Category: Cancer & Oncology Authors: Chalid Assaf Timothy M. Illidge Nathalie Waser Mary He Tina Li Athanasios Zomas Nawal Bent-Ennakhil Meredith Little Pablo L. Ortiz-Romero Nicola Pimpinelli Mehul Dalal Martine Bagot Tags: Article Source Type: research
Bridging the specialty gap: Update on primary cutaneous lymphomas
Primary cutaneous lymphoma (PCL), including both cutaneous T-cell lymphoma (CTCL) and cutaneous B-cell lymphoma (CBCL), should always be in the differential diagnosis for persistent patches or plaques unresponsive to usual therapies, expanding single or multiple tumors, and any erythroderma. Because patients with PCL typically present to dermatologists, a low threshold for skin biopsy is key to early diagnosis. Upon pathologic diagnosis, the informed dermatologist can initiate further evaluation and staging for the particular type of PCL. (Source: Journal of the American Academy of Dermatology)
Source: Journal of the American Academy of Dermatology - November 30, 2023 Category: Dermatology Authors: Elise A. Olsen, Emmilia Hodak, Larisa Geskin, Julia Scarisbrick, ISCL, USCLC, and EORTC-CLTG Tags: Research letter Source Type: research
Deciphering Tumor Cell Evolution in Cutaneous T-Cell Lymphomas: Distinct Differentiation Trajectories in Mycosis Fungoides and S ézary Syndrome
Cutaneous T-cell lymphomas are a heterogeneous group of neoplasms originating in the skin, with mycosis fungoides (MF) and S ézary syndrome (SS) representing the most common variants. The cellular origin of cutaneous lymphomas has remained controversial due to their immense phenotypic heterogeneity that obfuscates lineage reconstruction based on classical surface biomarkers. To overcome this heterogeneity and reconstruct the differentiation trajectory of malignant cells in MF and SS, T-cell receptor sequencing was performed in parallel with targeted transcriptomics at the single-cell resolution among cutaneous samples in ...
Source: Journal of Investigative Dermatology - November 28, 2023 Category: Dermatology Authors: Tony T. Jiang, Simon Cao, Oleg Kruglov, Aman Virmani, Larisa J. Geskin, Louis D. Falo, Oleg E. Akilov Tags: Original Article Source Type: research
Broadening the horizon: potential applications of CAR-T cells beyond current indications
Engineering immune cells to treat hematological malignancies has been a major focus of research since the first resounding successes of CAR-T-cell therapies in B-ALL. Several diseases can now be treated in highly therapy-refractory or relapsed conditions. Currently, a number of CD19- or BCMA-specific CAR-T-cell therapies are approved for acute lymphoblastic leukemia (ALL), diffuse large B-cell lymphoma (DLBCL), mantle cell lymphoma (MCL), multiple myeloma (MM), and follicular lymphoma (FL). The implementation of these therapies has significantly improved patient outcome and survival even in cases with previously very poor ...
Source: Frontiers in Immunology - November 27, 2023 Category: Allergy & Immunology Source Type: research
